首页> 外文期刊>Journal of Virological Methods >Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells
【24h】

Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells

机译:表达绿色绿色荧光蛋白的亚基因组CV-B3复制子的构建,用于评估培养的人类细胞中向心性肠病毒株的病毒复制

获取原文
获取原文并翻译 | 示例
           

摘要

Coxsackieviruses B (CV-B) (Picornaviridae) are a common infectious cause of acute myocarditis in children and young adults, a disease, which is a precursor to 10-20% of chronic myocarditis and dilated cardiomyopathy (DCM) cases. The mechanisms involved in the disease progression from acute to chronic myocarditis phase and toward the DCM clinical stage are not fully understood but are influenced by both viral and host factors. Subgenomic replicons of CV-B can be used to assess viral replication mechanisms in human cardiac cells and evaluate the effects of potential antiviral drugs on viral replication activities. Our objectives were to generate a reporter replicon from a cardiotropic prototype CV-B3/28 strain and to characterize its replication properties into human cardiac primary cells. To obtain this replicon, a cDNA plasmid containing the full CV-B3/28 genome flanked by a hammerhead ribozyme sequence and an Mlul restriction site was generated and used as a platform for the insertion of sequences encoding emerald green fluorescent protein (EmGFP) in place of those encoding VP3. In vitro transcribed RNA from this plasmid was transfected into HeLa cells and human primary cardiac cells and was able to produce EmGFP and VP1-containing polypeptides. Moreover, non-structural protein biological activity was assessed by the specific cleavage of elF4G1 by viral 2A(pro). Viral RNA replication was indirectly demonstrated by inhibition assays, fluoxetine was added to cell culture and prevented the EmGFP synthesis. Our results indicated that the EmGFP CV-B3 replicon was able to replicate and translate as well as the CV-B3/28 prototype strain. Our EmGFP CV-B3 replicon will be a valuable tool to readily investigate CV-B3 replication activities in human target cell models. (C) 2016 Elsevier B.V. All rights reserved.
机译:柯萨奇病毒B(CV-B)(Picornaviridae)是儿童和青少年急性心肌炎的常见传染病,是慢性心肌炎和扩张型心肌病(DCM)病例的10-20%的先兆。疾病从急性到慢性心肌炎发展到DCM临床阶段的机制尚不完全清楚,但受到病毒和宿主因素的影响。 CV-B的亚基因组复制子可用于评估人心脏细胞中的病毒复制机制,并评估潜在的抗病毒药物对病毒复制活性的影响。我们的目标是从心脏原型CV-B3 / 28菌株生成一个​​报告子复制子,并表征其复制特性到人心脏原代细胞中。为了获得此复制子,生成了一个cDNA质粒,该质粒包含完整的CV-B3 / 28基因组,其侧翼为锤头状核酶序列和一个MluI限制性酶切位点,并用作插入编码翡翠绿色荧光蛋白(EmGFP)的序列的平台那些编码VP3的视频。将来自该质粒的体外转录RNA转染到HeLa细胞和人原代心脏细胞中,并能够产生EmGFP和VP1多肽。此外,通过病毒2A(pro)对elF4G1的特异性切割来评估非结构蛋白的生物学活性。病毒RNA复制通过抑制试验间接证实,氟西汀被添加到细胞培养物中并阻止了EmGFP的合成。我们的结果表明EmGFP CV-B3复制子能够复制和翻译CV-B3 / 28原型菌株。我们的EmGFP CV-B3复制子将是一种很有价值的工具,可以很容易地研究人类靶细胞模型中的CV-B3复制活性。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号